참고문헌
- Anda T, Shabani HK, Tsunoda K, et al (2003). Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res, 25, 241-8. https://doi.org/10.1179/016164103101201445
- Bredel M (2001). Anticancer drug resistance in primary human brain tumors. Brain Res Rev, 35, 161-204. https://doi.org/10.1016/S0165-0173(01)00045-5
- Chen SD, Song MM, Zhong ZQ et al (2012). Knockdown of radixin by RNA interference suppresses the growth of human pancreatic cancer cells in vitro and in vivo. Asian Pac J Cancer Prev, 13, 753-9. https://doi.org/10.7314/APJCP.2012.13.3.753
- Cheng CL, Johnson SP, Keir ST, et al (2005). Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther, 4, 1364-8. https://doi.org/10.1158/1535-7163.MCT-05-0128
- Darakhshan S, Bidmeshkipour A, Khazaei M, et al (2013). Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev, 14, 6869-74. https://doi.org/10.7314/APJCP.2013.14.11.6869
- Fazeny-Dorner B, Wenzel C, et al (2003). Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs, 14, 305-12. https://doi.org/10.1097/00001813-200304000-00008
- Fontaine D, Vandenbos F, et al (2008). Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice. Rev Neurol (Paris), 164, 595-604. https://doi.org/10.1016/j.neurol.2008.04.002
- Forsyth PA, Wong H, Laing TD, et al (1999). Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer, 79, 1828-35. https://doi.org/10.1038/sj.bjc.6990291
- Gorlia T, van den Bent MJ, Hegi ME, et al (2008). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol, 9, 29-38. https://doi.org/10.1016/S1470-2045(07)70384-4
- Hoffman S, Propp JM, McCarthy BJ (2006). Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol, 8, 27-37. https://doi.org/10.1215/S1522851705000323
- Holden JA, Townsend JJ (1999). DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol, 12, 1094-100.
- Jadhav U, Chigurupati S, Lakka SS, Mohanam S (2004). Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol, 25, 1407-14.
- Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J (2003). Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol, 129, 477-84. https://doi.org/10.1007/s00432-003-0471-5
- Jin J, Cai L, Liu ZM, et al (2013). miRNA-218 inhibits osteosarcoma cell migration and invasion by downregulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev, 14, 3681-4. https://doi.org/10.7314/APJCP.2013.14.6.3681
- Kang SG, Kim JH, Nam DH, Park K (2005). Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol Med Chir, 45, 232-8; discussion 238-9. https://doi.org/10.2176/nmc.45.232
- Kidoikhammouan S, Seubwai W, Tantapotinan N, et al (2013). TNP-470, a methionine aminopeptidase-2 inhibitor, inhibits cell proliferation, migration and invasion of human cholangiocarcinoma cells in vitro. Asian Pac J Cancer Prev, 13, 155-60.
- Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE (2005). Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg, 103, 156-64. https://doi.org/10.3171/jns.2005.103.1.0156
- Kleihues P, Sobin LH (2000). World Health Organization classification of tumors. Cancer, 88, 2887. https://doi.org/10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F
- Lee SD (2008). Notice of retraction of “The experience with Ritleng intubation system in patients with congenital nasolacrimal duct obstruction”. 67, 344-8. J Chin Med Assoc, 71, 329. https://doi.org/10.1016/S1726-4901(08)70133-3
- Levicar N, Nuttall RK, Lah TT (2003). Proteases in brain tumour progression. Acta Neurochir (Wien), 145, 825-38. https://doi.org/10.1007/s00701-003-0097-z
- Li S, Jiang T, Wang Z (2008). Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res, 30, 567-70. https://doi.org/10.1179/174313208X297913
- Li SW, Qiu XG, Chen BS, et al (2009). Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J, 122, 1245-9.
- Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
- Lutterbach J, Sauerbrei W, Guttenberger R (2003). Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol, 179, 8-15.
- Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990). Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol, 8, 1277-80.
- Mineo JF, Bordron A, Baroncini M, et al (2007). Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir, 149, 245-52; discussion 252-43. https://doi.org/10.1007/s00701-006-1092-y
- Ng, SS, Cheung YT, An XM, et al (2007). Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma. J Natl Cancer Inst, 99, 936-48. https://doi.org/10.1093/jnci/djm011
- Park K, Kim J, Lim S, et al (2003).Topoisomerase II-alpha (topo II) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer, 39, 631-4. https://doi.org/10.1016/S0959-8049(02)00745-1
- Piroth MD, Gagel B, Pinkawa M, et al (2007). Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors. Strahlenther Onkol, 183, 695-702. https://doi.org/10.1007/s00066-007-1739-5
- Rao JS (2003). Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer, 3, 489-501. https://doi.org/10.1038/nrc1121
- Sabha N, Knobbe CB, Maganti M, et al (2014). Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol, 16, 914-923. https://doi.org/10.1093/neuonc/not299
- Saito T, Hama S, Kajiwara Y, et al (2006). Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas. Anticancer Res, 26, 1351-7.
- Sathornsumetee S, Rich JN (2006). New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther, 6, 1087-104. https://doi.org/10.1586/14737140.6.7.1087
- Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R (2010). Gliomas in adults. Dtsch Arztebl Int, 107, 799-807.
- Singh VY, Chacko G, Chacko AG, et al (2014). Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms. Neurol India, 62, 32-6. https://doi.org/10.4103/0028-3886.128275
- Smith JS, Jenkins RB (2000). Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci, 5, 213-31. https://doi.org/10.2741/Smith
- Smrdel U, Kovac V, Popovic M, Zwitter M (2014). Glioblastoma patients in Slovenia from 1997 to 2008. Radiol Oncol, 48, 72-9.
- Stojic J, Hagemann C, Haas S, et al (2008). Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res, 60, 40-9. https://doi.org/10.1016/j.neures.2007.09.009
- Stupp R, Hegi ME, van den Bent MJ, et al (2006). Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, 11, 165-80. https://doi.org/10.1634/theoncologist.11-2-165
- Stupp R, WP Mason, van den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-96. https://doi.org/10.1056/NEJMoa043330
- Stupp R, Pavlidis N, Jelic S (2005). ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol, 16, 64-5. https://doi.org/10.1093/annonc/mdi024
- Stupp R, Weber DC (2005). The role of radio-and chemotherapy in glioblastoma. Onkologie, 28, 315-7. https://doi.org/10.1159/000085575
- Taniguchi K, Wakabayashi T, Yoshida T, et al (1999). Immunohistochemical staining of DNA topoisomerase II alpha in human gliomas. J Neurosurg, 91, 477-82. https://doi.org/10.3171/jns.1999.91.3.0477
- Tramacere F, Gianicolo E, Serinelli M, et al (2008). Multivariate analysis of prognostic factors and survival in patients with “glioblastoma multiforme. Clin Ter, 159, 233-8.
- VanMeter TE, Rooprai HK, Kibble MM, et al (2001). The role of matrix metalloproteinase genes in glioma invasion: codependent and interactive proteolysis. J Neurooncol, 53, 213-35. https://doi.org/10.1023/A:1012280925031
- Wen PY, Yung WK, Lamborn KR, et al (2006). Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res, 12, 4899-907. https://doi.org/10.1158/1078-0432.CCR-06-0773
- Yahayo W, Supabpho A, Supabphol R (2013). Suppression of human fibrosarcoma cell metastasis by Phyllanthus emblica extract in vitro. Asian Pac J Cancer Prev, 14, 6863-7. https://doi.org/10.7314/APJCP.2013.14.11.6863
- Yong VW (2005). Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci, 6, 931-44. https://doi.org/10.1038/nrn1807
피인용 문헌
- Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma pp.1523-5866, 2018, https://doi.org/10.1093/neuonc/nox193
- Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study pp.1573-7373, 2018, https://doi.org/10.1007/s11060-017-2726-z